Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Diabetes, Obesity & Metabolism|March 4, 2016
Evolution of pharmacological obesity treatments: focus on adverse side-effect profilesA J Krentz, K Fujioka, M Hompesch
Diabetes, Obesity & Metabolism|May 15, 2015
Biosimilar insulins: guidance for data interpretation by clinicians and usersL Heinemann, P D Home, M Hompesch
Diabetes, Obesity & Metabolism|June 10, 2014
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metforminA J Krentz, L Morrow, M Petersson, et al.
Diabetes, Obesity & Metabolism|December 1, 2010
Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interactionL Morrow, M Hompesch, H Guthrie, et al.
Diabetes, Obesity & Metabolism|August 22, 2006
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groupsM Hompesch, B Troupin, T Heise, et al.
European Journal of Endocrinology|May 29, 2010
Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetesS M Ocheltree, M Hompesch, E T Wondmagegnehu, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|October 14, 2006
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetesM A Nauck, M Hompesch, R Filipczak, et al.
Diabetes, Obesity & Metabolism|January 10, 2012
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulinD Devineni, L Morrow, M Hompesch, et al.
Diabetologia|July 22, 2008
A novel insulin formulation with a more rapid onset of actionS Steiner, M Hompesch, R Pohl, et al.
Diabetes, Obesity & Metabolism|May 13, 2016
Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trialL A Morrow, M Hompesch, S J Jacober, et al.
Pageof 2